Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis

References

• National Multiple Sclerosis Society. MS prevalence. Available at: http://www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx [Last accessed 22 Jun 2013]
   Google Scholar
• Bainbridge JL, Rieckmann P. Multiple sclerosis. In: DiPiro JT, Talbert R, Yee G, Matzke G, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical, 2008:913-26
   Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22
   PubMed Web of Science ®Google Scholar
• Rolak LA. Multiple sclerosis: it's not the disease you thought it was. Clin Med Res 2003;1:57-60
   PubMedGoogle Scholar
• Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53:285-302
   PubMed Web of Science ®Google Scholar
• Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
   PubMedGoogle Scholar
• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
   PubMed Web of Science ®Google Scholar
• Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-66
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
   PubMedGoogle Scholar
• Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-8
   PubMed Web of Science ®Google Scholar
• Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
   PubMed Web of Science ®Google Scholar
• Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf 2013;5:37-47
   PubMedGoogle Scholar
• Calabresi PA, Goodin D, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis. Abstract presented at the 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, 10–13 October 2012. Lyon, France. Abstract available at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=156899&XNSPRACHE_ID=2&XNKONGRESS_ID=171&XNMASKEN_ID=900 [last accessed 22 Jun 2013]
   Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Comparison of compliance to fingolimod and other first-line disease modifying treatment among patients with multiple sclerosis. ACMP 2012 Education Conference, AMCP 2012 Education Conference, 3--5 October 2012, Cincinnati, OH, USA, 2012
   Google Scholar
• Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing–remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
   PubMed Web of Science ®Google Scholar
• Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 2008;40:281-90
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
   PubMedGoogle Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
   PubMedGoogle Scholar
• Graf C, Battisti WP, Bridges D, et al. Research methods & reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330, http://www.bmj.com/content/339/bmj.b4330
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9
   PubMed Web of Science ®Google Scholar
• Capkun-Niggli G, Lahoz R, Verdun E, et al. Medical and pharmacy claims-based algorithms for identifying relapses in patients with multiple sclerosis. ISPOR 16th Annual European Congress, 2–6 November 2013
   Google Scholar
• D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7
   PubMed Web of Science ®Google Scholar
• Roos LL, Stranc L, James RC, et al. Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 1997;32:229-38, discussion 39-42
   PubMed Web of Science ®Google Scholar
• Roskell NS, Zimovetz EA, Rycroft CE, et al. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Curr Med Res Opin 2012;28:767-80
   PubMed Web of Science ®Google Scholar
• Agashivala N, Wu N, Abouzaid S, et al. Comparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease modifying treatment. ECTRIMS 28th Congress of the European Committee, 10–13 October 2012
   Google Scholar